The investigational cancer vaccine, NOUS-209, was found to safely stimulate the immune system to target precancerous and cancerous cells in individuals with Lynch Syndrome (LS). The results of a Phase Ib/II clinical trial, led by Eduardo Vilar-Sanchez, M.D., Ph.D., chair ad interim of Clinical Cancer Prevention, provide early evidence that immune-based approaches, such as NOUS-209, may be able to intercept cancer before it develops, offering a potential new avenue for preventive care for high-risk individuals.   “Current management strategies for Lynch...

In a Phase I study, the novel monoclonal antibody linavonkibart, also known as SRK-181, demonstrated the potential to overcome treatment resistance to anti-PD-1 immune checkpoint inhibitors in multiple cancer types. The trial was led by Timothy Yap, M.B.B.S., Ph.D., professor of Investigational Cancer Therapeutics and vice president and head of clinical development in MD Anderson’s Therapeutics Discovery division.   “This is a very exciting trial because we’ve been trying to effectively target this protein, called transforming growth factor-beta 1, for a long...